Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377506 | 0.87 | KAT2B (0.69) | KAT2BTSHRCYP3A4ALDH1A1MAPT | |
| SCHEMBL24076 | 0.87 | KAT2B (0.69) | KAT2BTSHRCYP3A4ALDH1A1MAPT | |
| SCHEMBL11463783 | 0.86 | KAT2B (0.62) | KAT2BTSHRCYP3A4ALDH1A1MAPT | |
| SCHEMBL6250970 | 0.85 | KAT2B (0.66) | KAT2BTSHRCYP3A4ALDH1A1MAPT | |
| SCHEMBL29580274 | 0.84 | KAT2B (0.74) | KAT2BTSHRALDH1A1MAPTTDP1 | |
| SCHEMBL4858189 | 0.84 | KAT2B (0.74) | KAT2BTSHRALDH1A1MAPTTDP1 | |
| SCHEMBL16449995 | 0.83 | LMNA (0.60) | KAT2BALDH1A1MAPTTDP1KCNMA1 | |
| SCHEMBL4863416 | 0.83 | KAT2B (0.72) | KAT2BTSHRALDH1A1MAPTTDP1 | |
| SCHEMBL8655505 | 0.82 | KAT2B (0.56) | KAT2BTSHRCYP3A4ALDH1A1MAPT | |
| SCHEMBL18680085 | 0.82 | KAT2B (0.56) | KAT2BTSHRCYP3A4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371353-B1 | Thickened cationic cosmetic composition comprising inulin | WELLA AG (DE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1287812-B1 | Method of simultaneously dyeing and permanent waving the hair | WELLA AG (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050232888-A1 | Cosmetic compositions for hair care | WELLA AG (DE) | 2005-10-20 | — | — | US | disclosed |
| US-6945254-B2 | Method for simultaneously dyeing and permanent shaping of hair | WELLA AKTIENGESELLSCHAFT (DE) | 2005-09-20 | — | — | US | disclosed |
| EP-1371353-A1 | Thickened cationic cosmetic composition comprising inulin | Wella Aktiengesellschaft (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030084518-A1 | Method for simultaneously dyeing and permanent shaping of hair | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2003-05-08 | — | — | US | disclosed |
| EP-1287812-A2 | Method of simultaneously dyeing and permanent waving the hair | Wella Aktiengesellschaft (DE) | 2003-03-05 | — | — | EP | disclosed |
| EP-0863739-B1 | HAIR DYE | WELLA AG (DE) | 2002-04-17 | — | — | EP | disclosed |
| EP-0857476-A1 | Use of tanning agents to extend the shelf life of hair dyes | Wella Aktiengesellschaft (DE) | 1998-08-12 | — | — | EP | disclosed |
| EP-0852942-A1 | Composition for dyeing and tinting hair | Wella Aktiengesellschaft (DE) | 1998-07-15 | — | — | EP | disclosed |
| EP-0821935-A2 | Composition for dyeing and tinting hair | Wella Aktiengesellschaft (DE) | 1998-02-04 | — | — | EP | disclosed |
| EP-0806199-A2 | Composition and method for dyeing keratin fibres | Wella Aktiengesellschaft (DE) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232888-A1 | Cosmetic compositions for hair care | H1-0, H1-10, H1-2 | KAT2B 141/4885TSHR 2216/4885CYP3A4 4254/4885 |
| US-20030084518-A1 | Method for simultaneously dyeing and permanent shaping of hair | KRT18, KMO, TYR | KAT2B 533/4885TSHR 2074/4885CYP3A4 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.